NASDAQ
PRTA

Prothena Corporation plc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Prothena Corporation plc Stock Price

Vitals

Today's Low:
$54.16
Today's High:
$56.02
Open Price:
$54.19
52W Low:
$27.76
52W High:
$79.65
Prev. Close:
$54.45
Volume:
298981

Company Statistics

Market Cap.:
$2.91 billion
Book Value:
10.874
Revenue TTM:
$57.63 million
Operating Margin TTM:
-300.61%
Gross Profit TTM:
$-81657000
Profit Margin:
-244.45%
Return on Assets TTM:
-17.05%
Return on Equity TTM:
-28.49%

Company Profile

Prothena Corporation plc had its IPO on 2012-12-21 under the ticker symbol PRTA.

The company operates in the Healthcare sector and Biotechnology industry. Prothena Corporation plc has a staff strength of 127 employees.

Stock update

Shares of Prothena Corporation plc opened at $54.19 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $54.16 - $56.02, and closed at $55.39.

This is a +1.73% increase from the previous day's closing price.

A total volume of 298,981 shares were traded at the close of the day’s session.

In the last one week, shares of Prothena Corporation plc have increased by +0.44%.

Prothena Corporation plc's Key Ratios

Prothena Corporation plc has a market cap of $2.91 billion, indicating a price to book ratio of 6.9771 and a price to sales ratio of 549.2818.

In the last 12-months Prothena Corporation plc’s revenue was $57.63 million with a gross profit of $-81657000 and an EBITDA of $-172432000. The EBITDA ratio measures Prothena Corporation plc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Prothena Corporation plc’s operating margin was -300.61% while its return on assets stood at -17.05% with a return of equity of -28.49%.

In Q2, Prothena Corporation plc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 206.3%.

Prothena Corporation plc’s PE and PEG Ratio

Forward PE
64.1026
Trailing PE
0
PEG
0.8

Its diluted EPS in the last 12-months stands at $-2.78 per share while it has a forward price to earnings multiple of 64.1026 and a PEG multiple of 0.8. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Prothena Corporation plc’s profitability.

Prothena Corporation plc stock is trading at a EV to sales ratio of 453.1747 and a EV to EBITDA ratio of -14.794. Its price to sales ratio in the trailing 12-months stood at 549.2818.

Prothena Corporation plc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$720.65 million
Total Liabilities
$71.57 million
Operating Cash Flow
$-771000.00
Capital Expenditure
$771000
Dividend Payout Ratio
0%

Prothena Corporation plc ended 2024 with $720.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $720.65 million while shareholder equity stood at $581.68 million.

Prothena Corporation plc ended 2024 with $67.41 million in deferred long-term liabilities, $71.57 million in other current liabilities, 535000.00 in common stock, $-934462000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $659.11 million and cash and short-term investments were $659.11 million. The company’s total short-term debt was $3,448,000 while long-term debt stood at $0.

Prothena Corporation plc’s total current assets stands at $677.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $597000.00 compared to accounts payable of $13.85 million and inventory worth $10.67 million.

In 2024, Prothena Corporation plc's operating cash flow was $-771000.00 while its capital expenditure stood at $771000.

Comparatively, Prothena Corporation plc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$55.39
52-Week High
$79.65
52-Week Low
$27.76
Analyst Target Price
$93.44

Prothena Corporation plc stock is currently trading at $55.39 per share. It touched a 52-week high of $79.65 and a 52-week low of $79.65. Analysts tracking the stock have a 12-month average target price of $93.44.

Its 50-day moving average was $61.67 and 200-day moving average was $59.51 The short ratio stood at 9.69 indicating a short percent outstanding of 0%.

Around 471% of the company’s stock are held by insiders while 9921% are held by institutions.

Frequently Asked Questions About Prothena Corporation plc

The stock symbol (also called stock or share ticker) of Prothena Corporation plc is PRTA

The IPO of Prothena Corporation plc took place on 2012-12-21

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$39.63
-2.08
-4.99%
Cohu Inc (COHU)
$34.74
-0.19
-0.54%
$0.56
-0.01
-1.75%
$437.3
17.35
+4.13%
GHCL Limited (500171)
$630.45
1.95
+0.31%
$37.25
0.79
+2.17%
$14.65
-0.58
-3.81%
$0.2
0
0%
$67.48
3.21
+4.99%
$669.25
-5.4
-0.8%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Address

77 Sir John Rogerson?s Quay, Dublin, Ireland, 2